Mp100-11 percutaneous irreversible electroporation of renal tumors: outcomes after median 2 year follow-up

You have accessJournal of UrologyKidney Cancer: Ablative Therapy1 Apr 2017MP100-11 PERCUTANEOUS IRREVERSIBLE ELECTROPORATION OF RENAL TUMORS: OUTCOMES AFTER MEDIAN 2 YEAR FOLLOW-UP Igor Sorokin, Noah Canvasser, Aaron Lay, Monica Morgan, Asim Ozayar, Jeffrey Gahan, Clayton Trimmer, and Jeffrey Cadeddu Igor SorokinIgor Sorokin More articles by this author , Noah CanvasserNoah Canvasser More articles by this author , Aaron LayAaron Lay More articles by this author , Monica MorganMonica Morgan More articles by this author , Asim OzayarAsim Ozayar More articles by this author , Jeffrey GahanJeffrey Gahan More articles by this author , Clayton TrimmerClayton Trimmer More articles by this author , and Jeffrey CadedduJeffrey Cadeddu More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.3118AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Percutaneous irreversible electroporation (IRE) is a novel minimally invasive technique to treat small renal tumors. IRE uses an electric field to create nano-pores within cellular membranes resulting in subsequent apoptosis. Because IRE is athermal, it offers potential advantages to radiofrequency (RFA) and cryoablation. We report on the longest followup outcomes of IRE renal tumor ablation. METHODS We retrospectively reviewed all IRE cases completed at our institution from April 2013-June 2016. IRE was performed using the NanoKnife® commercial system and 15 cm monopolar probes (AngioDynamics, NY, USA). All procedures were performed with computed tomography (CT) guidance, under general anesthesia with paralytics, and with ablation synchronized to the cardiac cycle. A minimum of three months of follow-up with a contrast-enhanced CT scan was necessary to be included in the analysis. RESULTS A total of 39 tumors in 38 patients underwent irreversible electroporation. Mean tumor size was 2.0 cm with a median R.E.N.A.L nephrometry score of 5. Twenty-six patients (68%) were discharged the same day of the procedure and no major (Clavien grade III or higher) intraoperative or post-operative complications occurred. Initial treatment success rate was 92%; our three failures (8%) underwent salvage radiofrequency ablation. With a median follow-up of 25.2 months, two-year local recurrence-free survival was 76% for patients with biopsy confirmed renal cell carcinoma, 84% with biopsy confirmed or a history of renal cell carcinoma, and 90% for the intent-to-treat cohort (figure 1). CONCLUSIONS Percutaneous irreversible electroporation has suboptimal short-term local disease control results compared to thermal ablation in this series of small, low complexity tumors. Larger series and longer follow-up is still needed to determine the durability of this modality for renal cell carcinoma. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e1334 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Igor Sorokin More articles by this author Noah Canvasser More articles by this author Aaron Lay More articles by this author Monica Morgan More articles by this author Asim Ozayar More articles by this author Jeffrey Gahan More articles by this author Clayton Trimmer More articles by this author Jeffrey Cadeddu More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...